Sleep Architecture in Children With Common Phenotype of Obstructive Sleep Apnea

Abstract Background: Anesthetics, analgesics, and surgery may profoundly affect sleep architecture and aggravate sleep-related breathing disturbances. The authors hypothesized that patients with preoperative polysomnographic evidence of obstructive sleep apnea (OSA) would experience greater changes in these parameters than patients without OSA. Methods: After obtaining approvals from the Institutional Review Boards, consented patients underwent portable polysomnography preoperatively and on postoperative nights (N) 1, 3, 5, and 7 at home or in hospital. The primary and secondary outcome measurements were polysomnographic parameters of sleep-disordered breathing and sleep architecture. Results: Of the 58 patients completed the study, 38 patients had OSA (apnea hypopnea index [AHI] >5) with median preoperative AHI of 18 events per hour and 20 non-OSA patients had median preoperative AHI of 2. AHI was increased after surgery in both OSA and non-OSA patients (P < 0.05), with peak increase on postoperative N3 (OSA vs. non-OSA, 29 [14, 57] vs. 8 [2, 18], median [25th, 75th percentile], P < 0.05). Hypopnea index accounted for 72% of the postoperative increase in AHI. The central apnea index was low (median = 0) but was significantly increased on postoperative N1 in only non-OSA patients. Sleep efficiency, rapid eye movement sleep, and slow-wave sleep were decreased on N1 in both groups, with gradual recovery. Conclusions: Postoperatively, sleep architecture was disturbed and AHI was increased in both OSA and non-OSA patients. Although the disturbances in sleep architecture were greatest on postoperative N1, breathing disturbances during sleep were greatest on postoperative N3.

Download Full-text

Sleep Architecture in Night Shift Workers Police Officers with Obstructive Sleep Apnea-hypopnea Syndrome

Sleep Science ◽

10.5935/1984-0063.20170024 ◽

2017 ◽

Vol 10 (4) ◽

pp. 134-141 ◽

Cited By ~ 2

Author(s):

Selene Verde-Tinoco ◽

Rafael Santana-Miranda ◽

Romel Gutiérrez-Escobar ◽

Reyes Haro ◽

Joana Miranda-Ortiz ◽

...

Keyword(s):

Obstructive Sleep Apnea ◽

Sleep Apnea ◽

Police Officers ◽

Night Shift ◽

Sleep Architecture ◽

Shift Workers ◽

Obstructive Sleep ◽

Hypopnea Syndrome

Download Full-text

Sleep architecture in 22q11.2 microdeletion syndrome patients: polysomnographic study of prodromal signs of Parkinson's Disease and obstructive sleep apnea

Sleep Medicine ◽

10.1016/j.sleep.2019.11.792 ◽

2019 ◽

Vol 64 ◽

pp. S283

Author(s):

A. Ocampo-Garcés ◽

M. Diaz ◽

K. Villanueva ◽

T. Córdova ◽

J. Mauro ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Obstructive Sleep Apnea ◽

Sleep Apnea ◽

Sleep Architecture ◽

Microdeletion Syndrome ◽

Obstructive Sleep ◽

22Q11.2 Microdeletion

Download Full-text

358 Daridorexant Improves Sleep in Patients with Mild/Moderate Obstructive Sleep Apnea

SLEEP ◽

10.1093/sleep/zsab072.357 ◽

2021 ◽

Vol 44 (Supplement_2) ◽

pp. A143-A143

Author(s):

Marie-Laure Boof ◽

Ingo Fietze ◽

Katharina Lederer ◽

Anne-Sophie Guern ◽

Vincent Lemoine ◽

...

Keyword(s):

Obstructive Sleep Apnea ◽

Sleep Apnea ◽

Sleep Duration ◽

Sleep Onset ◽

Sleep Architecture ◽

Sleep Stages ◽

Apnea Hypopnea Index ◽

Treatment Difference ◽

Obstructive Sleep ◽

Sleep Parameters

Abstract Introduction Daridorexant is a dual orexin receptor antagonist developed for the treatment of insomnia. The effect of the highest phase-3 dose of 50 mg daridorexant on nighttime respiratory function was evaluated in patients with mild/moderate obstructive sleep apnea (OSA). This study showed that repeated doses of daridorexant had no clinically meaningful effect on the apnea-hypopnea index (AHI) or on peripheral oxygen saturation. In the same study, the effect on objective sleep parameters was also explored by polysomnography (PSG). Methods In this randomized, double-blind, placebo-controlled, two-period, crossover study, daridorexant or placebo was administered in each period once daily for 5 consecutive nights to 28 patients. Treatment difference (daridorexant – placebo) for total sleep time (TST), latency to persistent sleep (LPS), and wake after sleep onset (WASO) was analyzed for Night 5 using linear mixed-effects modeling. In addition, sleep was further explored based on sleep duration during each hour of PSG recording, duration of the different sleep phases (rapid eye movement [REM], non-REM [including N1 to N3 sleep stages]), as well as number and mean/longest duration of awakenings. Results Of 28 patients enrolled, 25 completed the study and were included in the analysis (n=15/10 with mild/moderate OSA; mean [standard deviation] AHI: 16.3 [8.2] events/h). One patient had mild insomnia symptoms at baseline. Compared to placebo, daridorexant prolonged mean TST by 38.8 min (90% confidence interval: 19.7–57.9), shortened mean LPS by 17.2 min (-35.5–1.02), and reduced mean WASO by 31.0 min (-47.3 to 14.7). Sleep architecture was maintained as no treatment differences in the duration of the evaluated sleep stages were observed when normalized to TST. Sleep duration was prolonged in the second part of the night. mean and longest duration of awakenings were decreased by a mean (90% CI) of 2.0 min (-3.1 to 0.9) and 16.3 min (-24.1 to -8.6), respectively, without treatment difference for the total number of awakenings. Conclusion Daridorexant improved objective sleep parameters in patients with mild to moderate OSA without modifying sleep architecture. Support (if any) Funded by Idorsia Pharmaceuticals Ltd.

Download Full-text